
Get the right diagnosis the first time
We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
Latest insights – webinars, stories and more
-
Syndromic testing webinar hubWatch our most recent webinars to learn how experts have incorporated syndromic testing into their diagnostic approach. Plus, get the latest insights on molecular diagnostics for infectious diseases.
-
New rapid test for meningitis/encephalitisRapid diagnosis of central nervous system infections is crucial for successful patient outcomes. That's why we've introduced a new syndromic panel that can differentiate 15 pathogens in around 1 hour.
-
Take your diagnostics to new heightsMeet the QIAstat-Dx Rise (coming soon), the newest member of the QIAstat-Dx family. The QIAstat-Dx Rise lifts multiplex syndromic testing to new heights, combining a quick and easy workflow with increased testing capacity.
-
Adopting a new approach to serve the community during COVID-19When COVID-19 struck in Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. Learn how she adopted syndromic testing to help provide fast answers and peace of mind to her community.
-
Can your testing platform talk to you?The QIAstat-Dx Analyzer can, with push notifications sent through the QIAsphere app. The app works in harmony with your local network to help you maximize productivity – learn more in our connectivity guide.
Voices from the field – how medical professionals are using syndromic diagnostics

Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris

Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA

Joshua Arant, Founder and Chief Operations Officer, Mako Medical
Why choose syndromic testing as a diagnostic tool?
-
Laboratory benefits
- Easy to set up a test, with less than one minute hands-on time
- Increased analytical sensitivity1,2,3 versus traditional methods
- Ct data and amplification curves visible for detected pathogens
-
Patient benefits
- Comprehensive results for more than 20 pathogens with faster turnaround times4 can support faster clinical decision making
- Associated with reduced hospital length of stay5, improved patient management6 and better outcomes7
-
Antimicrobial stewardship benefits
- Comprehensive results allow causative pathogens to be identified quickly
- Supports the use of a targeted therapeutic approach to reduce inappropriate antibiotic use8 and antibiotic duration8
-
Healthcare cost benefits
- A reduction in the need for follow-up testing, shorter hospital stays and more efficient testing can reduce overall healthcare costs9
Featured – resources for infectious disease diagnostics
-
A simple syndromic workflowSee how quick and intuitive syndromic testing can be. Use this interactive demo to try out the QIAstat-Dx Analyzer for yourself.
-
Top 3 considerations during respiratory seasonAs we enter respiratory season, one topic drawing attention is co-infections between influenza-like illnesses and COVID-19.
-
COVID-19 solutions and resourcesLearn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.
References
- Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
- Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
- Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
- Echavarria M, et al. (2018) J Clin Virol, 108:90–95
- Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
- Bouzid D, et al. (2020) J Hospital Infection, 337-338
- Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
- Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
- Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368
The QIAstat-Dx Analyzer, QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel are intended for in vitro diagnostic use.
The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents that cause meningitis and/or encephalitis, and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (CNS) infection.
The QIAstat-Dx ME Panel is intended for in vitro diagnostic use by laboratory professionals only.
Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual.